What is the latest SANOFICONR stock price?
The latest stored price for SANOFICONR is Rs 4,033.40 as of 2026-09-18.
gimli
SANOFICONR stock AI analysis
SANOFICONR Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
SANOFI CONS HEALTHC IND L is a small-cap stock in Healthcare. This Gimli page shows the latest available SANOFICONR price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹4,033.40
1W return
-1.37%
1M return
-6.99%
3M return
-18.49%
6M return
-5.75%
1Y return
-23.79%
Market cap
₹9,289.16 cr
PE
34.92
PB
26.70
ROE
+80.97%
ROCE
+102.32%
RSI
34.68
Turnover
₹1.76 cr
Why it can matter in screens
- Momentum: SANOFICONR is below 50DMA, below 200DMA; RSI is 34.68.
- Returns: 1D +1.10%, 1W -1.37%, 1M -6.99%, 3M -18.49%, 1Y -23.79%.
- Trend levels: 52W high ₹4,988.80, 52W low ₹3,926.00, off high -19.15%.
- Liquidity: latest turnover is ₹1.76 cr; volume vs 20D is +0.99%.
- Valuation/profitability: PE 34.92, PB 26.70, ROE +80.97%, ROCE +102.32%.
- Growth: 3Y sales CAGR +10.46%, 3Y profit CAGR +17.50%.
Quick Answers
Is SANOFICONR above its 50DMA and 200DMA?
SANOFICONR is below 50DMA, below 200DMA. The latest 50DMA is 4,369.15 and the latest 200DMA is 4,462.81.
What are SANOFICONR PE, ROE and ROCE?
SANOFICONR has PE 34.92, ROE +80.97%, and ROCE +102.32% in Gimli's latest available snapshot.
How has SANOFICONR performed recently?
SANOFICONR has returned -6.99% over 1 month, -18.49% over 3 months, and -23.79% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-06-30 | 235.70 cr | 95.60 cr | 68.80 cr | 29.87 |
| 2026-03-31 | 229.20 cr | 94.40 cr | 67.80 cr | 29.44 |
| 2025-12-31 | 251.00 cr | 94.40 cr | 66.50 cr | 28.87 |
| 2025-09-30 | 233.90 cr | 88.00 cr | 62.90 cr | 27.31 |
| 2025-06-30 | 220.90 cr | 82.40 cr | 60.70 cr | 26.36 |
| 2025-03-31 | 172.60 cr | 69.20 cr | 50.00 cr | 21.69 |
| 2024-12-31 | 180.70 cr | 64.30 cr | 44.30 cr | nan |
| 2024-09-30 | 159.90 cr | 66.10 cr | 45.00 cr | 19.54 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2025-12-31 | 878.00 cr | 334.10 cr | 240.10 cr | 104.27 |
| 2025-03-31 | 896.80 cr | 334.00 cr | 240.10 cr | 104.27 |
| 2024-12-31 | 716.20 cr | 255.30 cr | 181.00 cr | 78.59 |
| 2024-03-31 | 737.50 cr | 255.20 cr | 181.00 cr | 78.59 |
| 2023-12-31 | 544.30 cr | 221.30 cr | 164.90 cr | 71.60 |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2025-12-31 | 547.00 cr | 374.80 cr | 24.80 cr | 384.00 cr |
| 2024-12-31 | 431.30 cr | 326.90 cr | 20.30 cr | 273.00 cr |
| 2023-12-31 | 345.40 cr | 1.60 cr | 0.00 cr | 207.60 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2025-12-31 | 174.80 cr | 167.20 cr | n/a |
| 2024-12-31 | 439.00 cr | 429.10 cr | n/a |
| 2023-12-31 | -0.40 cr | -4.40 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +71.27% | +2.60% | +17.86% | +13.01% | +8.27% | +0.00% |
| 2026-03-31 | +71.27% | +2.76% | +17.57% | +13.63% | +8.40% | +0.00% |
| 2025-12-31 | +71.27% | +2.83% | +17.33% | +13.46% | +8.56% | +0.00% |
| 2025-09-30 | +71.27% | +2.94% | +17.21% | +13.34% | +8.58% | +0.00% |
| 2025-06-30 | +71.27% | +3.24% | +16.89% | +12.85% | +8.59% | +0.00% |
| 2025-03-31 | +60.40% | +4.53% | +25.48% | +15.09% | +9.59% | +0.00% |
| 2024-12-31 | +60.40% | +4.42% | +25.35% | +14.78% | +9.84% | +0.00% |
| 2024-10-10 | +60.40% | +4.87% | +24.51% | +13.52% | +10.22% | +0.00% |
| 2024-09-30 | +60.40% | +5.22% | +24.03% | +13.06% | +10.36% | +0.00% |
| 2024-09-06 | +60.40% | +6.03% | +22.81% | +11.45% | +10.77% | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 440,829.82 cr | 36.388220 | +15.50% | +11.45% |
| DIVISLAB | DIVI S LABORATORIES LTD | 248,876.81 cr | 85.407280 | +18.37% | +53.39% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 163,807.57 cr | 75.106636 | +17.33% | +35.67% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 128,608.22 cr | 65.670049 | +21.03% | +13.94% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 116,723.14 cr | 26.011308 | +16.04% | +10.70% |
| CIPLA | CIPLA LTD | 112,647.78 cr | 33.401961 | +10.25% | -11.64% |
| LAURUSLABS | LAURUS LABS LIMITED | 105,487.98 cr | 96.587446 | +21.77% | +111.64% |
| MAXHEALTH | MAX HEALTHCARE INS LTD | 102,122.47 cr | 70.799892 | +14.33% | -10.58% |
Try these prompts
- Analyze SANOFI CONS HEALTHC IND L with valuation, momentum and industry peers
- Compare SANOFICONR with other Healthcare stocks
- Show small-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View small-cap stocks
- Find stocks above 50DMA
- Compare SANOFICONR with other Healthcare stocks
Data snapshot: 2026-09-18. Not investment advice.